Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Michel Farnier. (2015) An evaluation of alirocumab for the treatment of hypercholesterolemia. Expert Review of Cardiovascular Therapy 13:12, pages 1307-1323.
Read now
Read now
Haralampos Milionis, George Liamis & Moses Elisaf. (2015) Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. Expert Opinion on Biological Therapy 15:2, pages 287-298.
Read now
Read now
Shirya Rashid & John JP Kastelein. (2013) PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Review of Cardiovascular Therapy 11:11, pages 1567-1577.
Read now
Read now
Paul Lee & Robert A Hegele. (2013) Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opinion on Investigational Drugs 22:11, pages 1411-1423.
Read now
Read now
Articles from other publishers (39)
Sandra Hummelgaard, Joachim Pold Vilstrup, Camilla Gustafsen, Simon Glerup & Kathrin Weyer. (2023) Targeting PCSK9 to tackle cardiovascular disease. Pharmacology & Therapeutics 249, pages 108480.
Crossref
Crossref
Nasreen Alsayed, Wael Almahmeed, Fahad Alnouri, Khalid Al-Waili, Hani Sabbour, Kadhim Sulaiman, Mohammad Zubaid, Kausik K. Ray & Khalid Al-Rasadi. (2022) Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update. Atherosclerosis 343, pages 28-50.
Crossref
Crossref
Samanwita Mandal, Deblina Chakrabarty, Arijit Bhattacharya, Joydeep Paul, Srijan Haldar & Kuntal Pal. (2021) miRNA regulation of G protein-coupled receptor mediated angiogenic pathways in cancer. The Nucleus 64:3, pages 303-315.
Crossref
Crossref
David Sinning & Ulf Landmesser. (2021) Neue lipidsenkende Substanzen. DMW - Deutsche Medizinische Wochenschrift 146:02, pages 92-101.
Crossref
Crossref
David Sinning & Ulf Landmesser. (2020) Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran). Current Cardiology Reports 22:12.
Crossref
Crossref
Thomas C. Roberts, Robert Langer & Matthew J. A. Wood. (2020) Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery 19:10, pages 673-694.
Crossref
Crossref
Young-Kook Kim. (2020) RNA Therapy: Current Status and Future Potential. Chonnam Medical Journal 56:2, pages 87.
Crossref
Crossref
Victor Sokolov, Gabriel Helmlinger, Catarina Nilsson, Kirill Zhudenkov, Stanko Skrtic, Bengt Hamrén, Kirill Peskov, Eva Hurt-Camejo & Rasmus Jansson-Löfmark. (2019) Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. Journal of Lipid Research 60:9, pages 1610-1621.
Crossref
Crossref
Yanli Zhang-James, Marc Vaudel, Olav Mjaavatten, Frode S. Berven, Jan Haavik & Stephen V. Faraone. (2019) Effect of disease-associated SLC9A9 mutations on protein–protein interaction networks: implications for molecular mechanisms for ADHD and autism. ADHD Attention Deficit and Hyperactivity Disorders 11:1, pages 91-105.
Crossref
Crossref
G.M. Anantharamaiah, David W. Garber, Dennis Goldberg, Eric Morrel, Geeta Datta, Mayakonda N. Palgunachari, Thomas C. Register, Susan E. Appt & C. Roger White. (2018) Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques. Journal of Lipid Research 59:11, pages 2075-2083.
Crossref
Crossref
F W Lohoff, J L Sorcher, A D Rosen, K L Mauro, R R Fanelli, R Momenan, C A Hodgkinson, L F Vendruscolo, G F Koob, M Schwandt, D T George, I S Jones, A Holmes, Z Zhou, M-J Xu, B Gao, H Sun, M J Phillips, C Muench & Z A Kaminsky. (2017) Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder. Molecular Psychiatry 23:9, pages 1900-1910.
Crossref
Crossref
Paul Lebeau, Khrystyna Platko, Ali A. Al-Hashimi, Jae Hyun Byun, Šárka Lhoták, Nicholas Holzapfel, Gabriel Gyulay, Suleiman A. Igdoura, David R. Cool, Bernardo Trigatti, Nabil G. Seidah & Richard C. Austin. (2018) Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. Journal of Biological Chemistry 293:19, pages 7329-7343.
Crossref
Crossref
Amir Abbas Momtazi, Maciej Banach, Matteo Pirro, Evan A. Stein & Amirhossein Sahebkar. (2017) MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. Clinical Reviews in Allergy & Immunology 54:2, pages 224-233.
Crossref
Crossref
Sarah J. Duellman, Thomas Machleidt, James J. Cali & Jolanta Vidugiriene. (2017) Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor. Journal of Lipid Research 58:8, pages 1722-1729.
Crossref
Crossref
Bharat N. Gawande, John C. Rohloff, Jeffrey D. Carter, Ira von Carlowitz, Chi Zhang, Daniel J. Schneider & Nebojsa Janjic. (2017) Selection of DNA aptamers with two modified bases. Proceedings of the National Academy of Sciences 114:11, pages 2898-2903.
Crossref
Crossref
Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R. Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D. Horton, Jorg Taubel, Ashley Brooks, Chamikara Fernando, Robert S. Kauffman, David Kallend, Akshay Vaishnaw & Amy Simon. (2017) A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. New England Journal of Medicine 376:1, pages 41-51.
Crossref
Crossref
Rahul Chaudhary, Jalaj Garg, Neeraj Shah & Andrew Sumner. (2017) PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology 9:2, pages 76.
Crossref
Crossref
Yanli Zhang-James & Stephen V. Faraone. (2016) Genetic architecture for human aggression: A study of gene-phenotype relationship in OMIM. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 171:5, pages 641-649.
Crossref
Crossref
Xavier Pintó & María Carmen García Gómez. (2016) Nuevos tratamientos para la hipercolesterolemia. Medicina Clínica 146:4, pages 172-177.
Crossref
Crossref
Xavier Pintó & María Carmen García Gómez. (2016) New agents for hypercholesterolemia. Medicina Clínica (English Edition) 146:4, pages 172-177.
Crossref
Crossref
Kapil Gadkar, James Lu, Srikumar Sahasranaman, John Davis, Norman A. Mazer & Saroja Ramanujan. (2016) Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach. Journal of Lipid Research 57:1, pages 46-55.
Crossref
Crossref
Juan Pedro-Botet & Xavier Pintó. (2016) Una visión actualizada del tratamiento hipolipemiante de alta intensidad en los pacientes de alto riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 28:1, pages 19-30.
Crossref
Crossref
Rodrigo Vazquez-Lombardi, Tri Giang Phan, Carsten Zimmermann, David Lowe, Lutz Jermutus & Daniel Christ. (2015) Challenges and opportunities for non-antibody scaffold drugs. Drug Discovery Today 20:10, pages 1271-1283.
Crossref
Crossref
Michael M. Page, Claudia Stefanutti, Allan Sniderman & Gerald F. Watts. (2015) Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Clinical Science 129:1, pages 63-79.
Crossref
Crossref
Bin Dong, Amar Bahadur Singh, Salman Azhar, Nabil G. Seidah & Jingwen Liu. (2015) High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels. Atherosclerosis 239:2, pages 364-374.
Crossref
Crossref
K. R. Henne, B. Ason, M. Howard, W. Wang, J. Sun, J. Higbee, J. Tang, K. C. Matsuda, R. Xu, L. Zhou, J. C. Y. Chan, C. King, D. E. Piper, R. R. Ketchem, M. L. Michaels, S. M. Jackson & M. W. Retter. (2015) Anti-PCSK9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity-Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor-Binding Enhancement. Journal of Pharmacology and Experimental Therapeutics 353:1, pages 119-131.
Crossref
Crossref
Claudia Stefanutti & Gilbert R. Thompson. (2014) Lipoprotein Apheresis in the Management of Familial Hypercholesterolaemia: Historical Perspective and Recent Advances. Current Atherosclerosis Reports 17:1.
Crossref
Crossref
Michel Farnier. 2015. Combination Therapy In Dyslipidemia. Combination Therapy In Dyslipidemia
99
117
.
David W. Garber, Dennis Goldberg & G. M. Anantharamaiah. 2015. Apolipoprotein Mimetics in the Management of Human Disease. Apolipoprotein Mimetics in the Management of Human Disease
135
156
.
Brandon Ason, José W.A. van der Hoorn, Joyce Chan, Edward Lee, Elsbet J. Pieterman, Kathy Khanh Nguyen, Mei Di, Susan Shetterly, Jie Tang, Wen-Chen Yeh, Margrit Schwarz, J. Wouter Jukema, Rob Scott, Scott M. Wasserman, Hans M.G. Princen & Simon Jackson. (2014) PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Journal of Lipid Research 55:11, pages 2370-2379.
Crossref
Crossref
K Gadkar, N Budha, A Baruch, J D Davis, P Fielder & S Ramanujan. (2014) A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. CPT: Pharmacometrics & Systems Pharmacology 3:11, pages 1-9.
Crossref
Crossref
Francine K. Welty. (2014) Hypobetalipoproteinemia and abetalipoproteinemia. Current Opinion in Lipidology 25:3, pages 161-168.
Crossref
Crossref
Michael M. Page, Damon A. Bell, Amanda J. Hooper, Gerald F. Watts & John R. Burnett. (2014) Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, pages 387-403.
Crossref
Crossref
Majambu Mbikay, Francine Sirois, Sonia Simoes, Janice Mayne & Michel Chrétien. (2014) Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio 4:1, pages 755-762.
Crossref
Crossref
Michel Farnier. (2014) PCSK9: From discovery to therapeutic applications. Archives of Cardiovascular Diseases 107:1, pages 58-66.
Crossref
Crossref
Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga-Morskaya, Abigail Liebow, Brian R Bettencourt, Jessica E Sutherland, Renta M Hutabarat, Valerie A Clausen, Verena Karsten, Jeffrey Cehelsky, Saraswathy V Nochur, Victor Kotelianski, Jay Horton, Timothy Mant, Joseph Chiesa, James Ritter, Malathy Munisamy, Akshay K Vaishnaw, Jared A Gollob & Amy Simon. (2014) Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet 383:9911, pages 60-68.
Crossref
Crossref
Wilbert S AronowGeetha MukerjiRawand M AbdinDominic S Ng. 2013. Advances in Dyslipidemia. Advances in Dyslipidemia
42
57
.
Majambu Mbikay, Janice Mayne & Michel Chrétien. (2013) Proprotein Convertases Subtilisin/Kexin Type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (第9型前蛋白转换酶-枯草溶菌素/蛋白酶K，一种酶转变的护送蛋白：在肝脏与肝外的功能). Journal of Diabetes 5:4, pages 391-405.
Crossref
Crossref
Michel Farnier. (2013) PCSK9 inhibitors. Current Opinion in Lipidology 24:3, pages 251-258.
Crossref
Crossref